Parallel Advisors’s Lifecore Biomedical LFCR Stock Holding History

Parallel Advisors’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-225	Closed	-$1.15K	–	3442
2024 Q2	$1.15K	Buy	+225	New	+$1.33K	﹤0.01%	2925
2023 Q4	–	Sell	-225	Closed	-$1.7K	–	3398
2023 Q3	$1.7K	Hold	225	–	–	﹤0.01%	2868
2023 Q2	$2.18K	Buy	+225	New	+$1.37K	﹤0.01%	2734
2020 Q3	–	Sell	-98	Closed	–	–	2629
2020 Q2	$0	Buy	+98	New	+$1.01K	﹤0.01%	2592

Other funds holding LFCR

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

325 Capital New York $274M AUM 49.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parallel Advisors's LFCR Position: Q3 2024 in Review

Parallel Advisors sold out of Lifecore Biomedical (LFCR) in Q3 2024, closing a stake of 225 shares — an estimated $1.15K sold.

Parallel Advisors first reported a position in LFCR in Q2 2020 and held it in 4 quarters. The position peaked at $2.18K in Q2 2023. 82 funds tracked by Wall St. Rank hold LFCR as of Q3 2024.

Parallel Advisors reported no remaining Lifecore Biomedical position as of Q3 2024 after selling out during the quarter.
Parallel Advisors sold 225 Lifecore Biomedical shares in Q3 2024, an estimated $1.15K.
Parallel Advisors first reported a position in Lifecore Biomedical in Q2 2020 and held it in 4 quarters.
Parallel Advisors's Lifecore Biomedical position peaked at $2.18K in Q2 2023.
82 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2024.

Based on Parallel Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.